Overview of fibrillary glomerulonephritis (FGN)

Fibrillary glomerulonephritis (FGN) is a rare kidney disease that affects the glomeruli, which are the tiny filtering units in the kidneys. The main characteristic of FGN is the presence of these microscopic fibres, or fibrils, in the glomeruli. These fibrils are extremely small, measuring between 10 to 30 nanometers in diameter.¹³ To put this in perspective, they're about 1000 times thinner than a human hair. The fibrils are arranged randomly, like a tangled mess of threads, and they accumulate in the glomeruli over time.¹ The hallmark of FGN is the presence of fibrillary deposits in the glomeruli, which are made up of immunoglobulins and other proteins. Unlike amyloid fibrils, the fibrils in FGN do not stain with Congo red, which helps distinguish FGN from amyloidosis.⁴

The presence of these immune deposits triggers an inflammatory response in the glomeruli, thus contributing to the progressive damage of the glomerular structure.⁵

FGN is an uncommon disorder, with studies indicating it is present in only 0.5% to 1.4% of native kidney biopsies.⁶ FGN typically affects adults, with the average age of diagnosis being around 50 years old.³ Furthermore, FGN affects men and women equally. Racial distribution data suggests FGN is more commonly diagnosed in Caucasians (white people). In a study conducted at the Mayo Clinic, 95% of FGN patients were white.

The quality of life (QoL) is a multidimensional construct that encompasses physical, psychological, and social functioning aspects affected by a person's disease and/or treatment.⁷ In the context of chronic diseases, health-related quality of life (HRQoL) has emerged as a crucial measure to evaluate the impact of a disease, and the effectiveness of medical interventions.⁸ 

FGN is a rare but serious kidney disease with a generally poor prognosis. Many patients progress to end-stage kidney disease (ESKD) within several years of diagnosis. Regular QoL assessment can help track the impact of disease progression on patients' well-being and guide interventions to improve QoL.⁹ Kidney diseases often have far-reaching effects on patients' social lives and economic status. QoL assessment can help identify areas where patients may need additional support, such as financial counselling or social services.¹⁰ Patients with FGN may have co-occurring conditions, which is common in many chronic diseases. QoL assessment can provide a more comprehensive picture of the patient's overall health status and guide management of multiple conditions.⁸

Clinical symptoms and their impact on quality of life

The gradual loss of kidney function is a hallmark of FGN, with profound effects on patients' daily activities and overall health. As the disease progresses, patients often experience a decline in their glomerular filtration rate (GFR), leading to the accumulation of waste products in the blood.² This decline in renal function can manifest as fatigue, weakness, and decreased energy levels, which significantly impacting patients' ability to perform routine tasks and maintain their usual lifestyle.¹¹

The impact of renal function decline on physical health is multifaceted. Patients may experience anaemia due to decreased erythropoietin production, leading to further fatigue and reduced exercise tolerance. Additionally, the kidneys' diminished ability to regulate electrolytes and maintain fluid balance can result in various symptoms, including nausea, loss of appetite, and sleep disturbances. These symptoms collectively contribute to a reduced quality of life, often limiting patients' social interactions and ability to work or engage in leisure activities.¹²

Proteinuria, the excessive loss of protein in the urine, is a common symptom of FGN that can significantly impact patients' QoL.² The presence of proteinuria contributes to oedema, fatigue and malaise, further compounding the effects of renal function decline.¹³ Hypertension (high blood pressure) is a common complication of FGN that presents its own set of challenges and impacts on QoL.¹¹ The effects of hypertension on cardiovascular health are a significant concern for FGN patients. The increased risk of heart disease and stroke associated with persistent hypertension can lead to anxiety about long-term health outcomes.¹²

Treatment-related impact

Patients with FGN often require a complex medication regimen to manage their condition and associated symptoms, such as hypertension and proteinuria. This polypharmacy can be burdensome, leading to challenges in medication adherence and increased risk of drug interactions. Managing multiple medications requires careful coordination and regular monitoring, which can be stressful for patients and caregivers alike.² Immunosuppressive drugs, such as corticosteroids, are commonly used in the treatment of FGN to reduce inflammation and slow disease progression. However, these drugs come with significant side effects.

Corticosteroids, for example, can cause weight gain, hypertension, diabetes, osteoporosis, and increased susceptibility to infections.¹⁴ Cyclophosphamide, another immunosuppressive agent, can lead to bone marrow suppression, increased risk of infections, and potential long-term risks, such as secondary cancers. These side effects can significantly impact patients' quality of life and overall health.¹⁵

For patients who progress to end-stage kidney disease (ESKD), dialysis becomes a necessary treatment option. Dialysis requires significant time commitment, with patients typically undergoing treatment several times a week, for several hours each session. This can lead to substantial lifestyle changes, including restrictions on travel and daily activities.¹⁵

Kidney transplantation offers a potential cure for ESKD, but it comes with its own set of challenges. The physical impact of transplantation includes the risks associated with major surgery, and the need for lifelong immunosuppressive therapy to prevent organ rejection. These immunosuppressive drugs can have severe side effects, including increased susceptibility to infections and certain cancers.¹⁶ Psychologically, the uncertainty of transplant success and the potential for organ transplant rejection can cause significant stress and anxiety for patients and their families. The physical and emotional toll of dialysis can be considerable, often resulting in fatigue, depression, and anxiety.¹³

Managing FGN requires frequent medical appointments for monitoring kidney function, adjusting treatments, and addressing complications. These regular visits can be time-consuming and stressful, particularly for patients who may already be dealing with the physical and emotional burden of their disease. The need for constant medical attention can disrupt daily routines and add to the overall stress of managing a chronic illness.¹³ The frequent medical appointments and need for ongoing treatment can significantly impact a patient's ability to maintain employment and social relationships. Time away from work for medical visits, and the physical limitations imposed by the disease and its treatments, can lead to job loss or reduced work hours. Socially, the restrictions on activities and the need for constant medical care can lead to isolation and decreased quality of life.¹³

Psychological and emotional impact

Patients with FGN often experience high levels of stress due to the unpredictable nature of the disease, and the constant threat of kidney function decline.¹⁷ This chronic stress can manifest as anxiety and depression, which are common among patients with kidney diseases.¹⁸ The fear of progressing to ESRD, and potentially requiring dialysis or kidney transplantation, can be particularly distressing.²

The psychological impact of FGN is further compounded by the physical symptoms and treatment burden. Patients may experience fatigue, swelling, and hypertension, which can significantly affect their quality of life.² Additionally, the need for frequent medical appointments, dietary restrictions, and medication regimens can be overwhelming and contribute to feelings of loss of control.

Coping mechanisms and mental health support play crucial roles in managing the psychological aspects of FGN. Mental health interventions, such as counselling and support groups, can help patients develop effective coping strategies and improve their emotional well-being.¹⁹ A strong support system, including family, friends, and healthcare providers, is essential in helping patients navigate the challenges of living with FGN.

Access to care and health disparities significantly impact the psychological experience of FGN patients. Socioeconomic status can affect treatment access, with lower-income patients potentially facing barriers to specialised care and mental health support. Regional disparities in healthcare availability could further exacerbate these challenges, leading to increased stress and anxiety for patients in underserved areas.¹⁸

Role of patient advocacy

Importance of patient advocacy in improving quality of life

Patient advocacy plays a crucial role in improving the QoL for individuals with FGN. Advocates can help patients navigate the complexities of their condition, including understanding treatment options and managing symptoms, such as proteinuria and hypertension. Advocacy groups provide essential support, resources, and information, which can empower patients to make informed decisions about their care. This empowerment can lead to better health outcomes and improved QoL by ensuring patients receive the most appropriate and timely interventions.²

Engagement in decision-making and self-management

Engagement in decision-making and self-management is vital for patients with FGN. Active participation in their healthcare allows patients to tailor treatment plans to their specific needs and preferences, which can enhance adherence to therapies and overall satisfaction with care. Self-management strategies, such as monitoring blood pressure and adhering to dietary restrictions, are essential in managing the symptoms and slowing the progression of the disease. Patient advocacy organisations often provide education and tools to support these self-management practices, further enhancing patient autonomy and health outcomes.¹³

Summary

Fibrillary glomerulonephritis (FGN) is a rare kidney disease found in approximately 1% of native kidney biopsies.^6,20 FGN has a poor prognosis, with nearly half of patients progressing to end-stage renal disease within three years of diagnosis. FGN can be associated with underlying conditions, such as malignancies, dysproteinemias, and autoimmune diseases. Treatment options remain limited, with immunosuppressive therapy showing inconsistent results.²¹ The disease can recur in kidney transplant recipients. Given its rarity and impact on renal function, further research is needed to understand FGN's effects on patients' quality of life, and to develop targeted interventions.⁶ Potential areas for investigation include the psychological burden of the disease, impact on daily activities, and strategies to improve patient outcomes and well-being.